Eleonora Diamanti, Annina M. Steinbach, Lais P. de Carvalho, Henni-Karoliina Ropponen, Antoine Lacour, Rawia Hamid, Sidra Eisa, Patricia Bravo, Spyridon Bousis, Boris Illarionov, Markus Fischer, Mostafa M. Hamed, Nina C. Bach, Matthias Rottmann, Jana Held, Matthias Witschel, Stephan A. Sieber and Anna K. H. Hirsch*,
{"title":"Targeting the Plasmodium falciparum IspE Enzyme","authors":"Eleonora Diamanti, Annina M. Steinbach, Lais P. de Carvalho, Henni-Karoliina Ropponen, Antoine Lacour, Rawia Hamid, Sidra Eisa, Patricia Bravo, Spyridon Bousis, Boris Illarionov, Markus Fischer, Mostafa M. Hamed, Nina C. Bach, Matthias Rottmann, Jana Held, Matthias Witschel, Stephan A. Sieber and Anna K. H. Hirsch*, ","doi":"10.1021/acsomega.4c0603810.1021/acsomega.4c06038","DOIUrl":null,"url":null,"abstract":"<p >The enzyme IspE in <i>Plasmodium falciparum</i> is considered an attractive drug target, as it is essential for parasite survival and is absent in the human proteome. Yet it still has not been addressed by a small-molecule inhibitor. In this study, we conducted a high-throughput screening campaign against the <i>Pf</i>IspE enzyme. Our approach toward a <i>Pf</i>IspE inhibitor comprises <i>in vitro</i> screening, structure–activity relationship studies, examining the docking position using an AlphaFold model, and finally target verification through probe binding and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis. The newly synthesized probe containing a diazirine and an alkyne moiety (<b>23</b>) allowed us to demonstrate its binding to IspE in the presence of a lysate of human cells (HEK293 cells) and to get evidence that both probe <b>23</b> and the best inhibitor of the series (<b>19</b>) compete for the same IspE binding site.</p>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.acs.org/doi/epdf/10.1021/acsomega.4c06038","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"92","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsomega.4c06038","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0
Abstract
The enzyme IspE in Plasmodium falciparum is considered an attractive drug target, as it is essential for parasite survival and is absent in the human proteome. Yet it still has not been addressed by a small-molecule inhibitor. In this study, we conducted a high-throughput screening campaign against the PfIspE enzyme. Our approach toward a PfIspE inhibitor comprises in vitro screening, structure–activity relationship studies, examining the docking position using an AlphaFold model, and finally target verification through probe binding and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis. The newly synthesized probe containing a diazirine and an alkyne moiety (23) allowed us to demonstrate its binding to IspE in the presence of a lysate of human cells (HEK293 cells) and to get evidence that both probe 23 and the best inhibitor of the series (19) compete for the same IspE binding site.